Navigation Links
Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Date:9/23/2010

o TAXUS (7.4 percent for XIENCE V vs. 11.4 percent for TAXUS, p-value=0.0038).

In addition, XIENCE V demonstrated a 77 percent lower rate of stent thrombosis, defined as definite or probable according to ARC (0.9 percent for XIENCE V vs. 3.9 percent for TAXUS, p-value=<0.0001); a 60 percent lower rate of TVR (3.1 percent for XIENCE V vs. 7.7 percent for TAXUS, p-value=<0.0001); a 56 percent lower rate of TLR (2.6 percent XIENCE V vs. 5.9 percent TAXUS, p-value=0.0005); and a 49 percent lower rate of non-fatal MI (3.9 percent XIENCE V for vs. 7.6 percent for TAXUS, p-value=0.0009).

The stent thrombosis rate for XIENCE V between one and two years increased from 0.7 percent at one year to 0.9 percent at two years, while the TAXUS arm increased from 2.6 percent at one year to 3.9 percent at two years. At two years, 88.6 percent of XIENCE V patients and 84.8 percent of TAXUS patients had discontinued dual-antiplatelet therapy.

"The COMPARE results show that the gap in stent thrombosis rates between XIENCE V and TAXUS Liberte widened from 1.9 percent at one year to 3.0 percent at two years," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "The COMPARE investigators have provided some of the first major insights into the comparative long-term differences in stent thrombosis rates between one and two years for different stent platforms."

"The two-year results presented today for the COMPARE trial and for the SPIRIT IV trial demonstrate impressive outcomes for XIENCE V compared to TAXUS Liberte and TAXUS Express, respectively," said Robert Hance, senior vice president, vascular, Abbott. "Both of these trials show the differences in the performance of these drug eluting stents and add to the ever-growing body of safety and efficacy data for XIENCE V – reinforcing why XIENCE V continues to be the market-leading drug eluting stent."

About The
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
2. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
3. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
4. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
7. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
8. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
9. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MOINES, Iowa , Jan. 23, 2015  The Partnership to Fight ... Iowa health care leaders and a new study analyzing ... medications. The PFCD is a nationwide coalition working to educate policy ... research released at the Capitol was focused on how the ...
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third of ... of those with private insurance, filled a prescription for an ... report in this week,s Morbidity and Mortality Weekly Report (MMWR). ... providers to treat moderate to severe pain.  They are also ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Show 26% Partial Response, 63% Clinical Benefit ... ... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today announced that its lead ... Phase 2,trial when administered in combination with trastuzumab (Herceptin(R)) to,patients with ...
... Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients, ... ENMD ), a clinical-stage pharmaceutical company developing,therapeutics ... today,announced the presentation of clinical data for the ... cancer. The data were presented by Bryan P.,Schneider, ...
Cached Medicine Technology:Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 2EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 3EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting 4
(Date:1/22/2015)... 23, 2015 The U.S. Pharmacopeial Convention ... Director of Clinical Pharmacy Services at North Carolina State’s ... of the 2015 Beal Award for Distinguished Volunteer Service—the ... relied on the contributions of volunteer experts to direct ...
(Date:1/22/2015)... 2015 The City of West Hollywood hosted a ... commemorate the 42nd anniversary of the Supreme Court decision Roe v. ... 42 years since the Roe vs. Wade decision and the fight ... as ever,” said City of West Hollywood Councilmember Abbe Land. “We ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... replacement complication rates, longer hospital stays for obese patientsLAS ... obesity is rising at alarming speeds across the United ... be putting their long-term musculoskeletal function in jeopardy, according ... of the American Academy of Orthopaedic Surgeons ...
... many children at risk for foot deformity due to wrong ... wearing shoes that are too small, according to a new ... American Academy of Orthopaedic Surgeons ( http://www.aaos.org/ ) ... risk for developing serious foot deformities.The study, which took place ...
... referred for psychiatric services following an emergency room visit ... they call for help, compared to about 20 percent ... 10 percent of all calls to mental health clinics ... within two weeks, according to a new University of ...
... available in French . , The countries ... to build research capacity and conduct clinical trials under best ... for the conduct of clinical trials) is the first EDCTP-funded ... high-quality clinical trials. It will be supported by a EUR ...
... root causes of defects on the production , lineOTTAWA, ... quality systems are used by companies around the world ... has been named a preferred supplier to one of ... in a key growth market for the company. , ...
... Smith & Nephew,s,Orthopaedics business and BrainLAB today ... exclusive vendor for developing and supporting,computer-assisted surgical technologies ... implants. , Starting in ... Smith & Nephew portfolio of instruments, implants and ...
Cached Medicine News:Health News:Obesity: A Musculoskeletal Nightmare 2Health News:Obesity: A Musculoskeletal Nightmare 3Health News:Obesity: A Musculoskeletal Nightmare 4Health News:If the Shoe Fits...or Does It? 2Health News:If the Shoe Fits...or Does It? 3Health News:For psychiatric services, wait for the beep 2Health News:For psychiatric services, wait for the beep 3Health News:CANTAM first African Network of Excellence for clinical trials 2Health News:Sciemetric makes the grade with major medical device manufacturer 2Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 2Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 3Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: